Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meropenem + Colistin vs Imipenem/Cilastatin + Tigecycline for MDR Bacterial Infections
NCT07524920Phase 2Not yet recruiting
- Sponsor
- Ain Shams University
- Start
- Apr 2026
- Primary completion
- Aug 2026
- Modality
- Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of meropenem, colistin, imipenem + cilastatin, tigecycline in bacterial infection, sponsored by Ain Shams University. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
meropenemcolistinimipenem + cilastatintigecycline
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT07524920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07524920.